Clinical Trials on Bladder Urothelial Cancer

Total 52949 results

Seoul National University Hospital

Unknown

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer

Urothelial Carcinoma
Matthew Galsky
Celgene

Terminated

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Bladder Cancer

United States
Dana-Farber Cancer Institute
EMD Serono; National Comprehensive Cancer Network

Recruiting

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

Bladder Cancer | Urothelial Carcinoma | Metastatic Bladder Cancer | Unresectable Bladder Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Suspended

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO)

Clear Cell Renal Cell Carcinoma | Head and Neck Cancer | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Biliary Tract Cancer | Urothelial Bladder Cancer | Gastro-oesophageal Adenocarcinoma | Platinum-sensitive Urothelial Bladder Cancer

France
Vanderbilt University
Element Diagnostics

Completed

Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder

Bladder Cancer, Biomarkers

United States
Centre Hospitalier Universitaire Vaudois

Recruiting

Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better? (BWash)

Bladder Cancer

Switzerland
IRCCS San Raffaele
High Research

Recruiting

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

Urothelial Carcinoma

Italy
Assiut University

Recruiting

A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder

Bladder Cancer

Egypt
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Confocal Laser Endomicroscopy in the Lower Urinary Tract

Urothelial Carcinoma | Bladder Neoplasm

Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC (Indi-Blade)

Bladder Cancer | Urothelial Carcinoma

Netherlands
Jason R. Brown
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Bladder Cancer | Urothelial Carcinoma

United States
Technical University of Munich
Bristol-Myers Squibb

Active, not recruiting

Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder (RACE IT)

Urinary Bladder Cancer

Germany
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Metastatic Bladder Cancer | Non-Transitional Cell Carcinoma of the Urothelial Tract | Small Cell of the Bladder

United States
Spanish Oncology Genito-Urinary Group
Bristol-Myers Squibb

Recruiting

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer (VEXILLUM)

Urothelial Cancer

Spain
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Urothelial Cancer

United States, Argentina, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Singapore, Spain, Switzerland, Taiwan, Thailand and more
Fundacion CRIS de Investigación para Vencer el...
GlaxoSmithKline; Apices Soluciones S.L.; Ipsen

Active, not recruiting

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA)

Urothelial Cancer

Spain
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
University of Chicago

Completed

Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer

Urothelial Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)

Urothelial Cancer

Russian Federation, United States, Brazil, Spain, Chile, Korea, Republic of, Argentina, Australia, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Norway, Peru, Poland, Romania, Swed... and more
AstraZeneca

Active, not recruiting

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Urothelial Cancer

United States, Belgium, Denmark, Germany, Italy, Spain, Canada, Poland, Taiwan, France, Korea, Republic of, Netherlands, United Kingdom, Brazil, Japan, Mexico, Russian Federation, Turkey, China, Austria, Australia, Israel, Portugal, G...
Canadian Cancer Trials Group
Celgene; Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Completed

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Urothelial Cancer

Canada, Australia
RenJi Hospital

Recruiting

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

Urothelial Carcinoma Bladder | PD-1 Inhibitor

China
Ontario Clinical Oncology Group (OCOG)
Cancer Care Ontario

Active, not recruiting

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging (PET MUSE)

Muscle-invasive Bladder Cancer

Canada
University of Florida

Not yet recruiting

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

Urothelial Carcinoma Bladder
Infinity Pharmaceuticals, Inc.
Bristol-Myers Squibb

Completed

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Solid Tumor | Bladder Cancer | Advanced Cancer | Urothelial Carcinoma

France, Spain, United States, Italy, Czechia, Poland, Serbia
Abramson Cancer Center of the University of Pennsylvania

Completed

Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer

Urothelial Carcinoma of the Bladder

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Active, not recruiting

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Bladder Cancer | Urothelial Carcinoma | Metastatic Bladder Cancer

United States
Pierre Fabre Medicament
Bristol-Myers Squibb

Completed

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

Bladder Cancer | Bladder Neoplasms | Transitional Cell Carcinoma of the Urothelial Tract

Canada
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Not yet recruiting

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Bladder Cancer
Jens Nielsen
Göteborg University

Completed

Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma

Bladder Cancer

Sweden
Noah Hahn, M.D.
Novartis Pharmaceuticals; Hoosier Cancer Research Network

Terminated

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Bladder Cancer

United States
University of Michigan Rogel Cancer Center
Pfizer

Terminated

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

Bladder Cancer

United States
Nucleix Ltd.

Completed

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma

Bladder Cancer

Netherlands, Israel, Germany, Spain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

An Phase III Study, Multicenter，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Bladder Cancer

China
Ho Kyung Seo

Not yet recruiting

Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma

Bladder Cancer
Hoffmann-La Roche
Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Bladder Cancer | Urothelial Carcinoma

United States, Spain, Korea, Republic of, United Kingdom, Taiwan, France, Greece
Erasmus Medical Center

Recruiting

Safely Reduce Cystoscopic Evaluations for Hematuria Patients (SeARCH)

Bladder Cancer | Urothelial Carcinoma | Hematuria | Urothelial Neoplasm

Netherlands
Gilead Sciences
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (TROPHY U-01)

Metastatic Urothelial Cancer

Italy, United States, Korea, Republic of, Spain, Greece, France, Germany, United Kingdom, Turkey
Matthew Galsky
Bristol-Myers Squibb; Hoosier Cancer Research Network

Active, not recruiting

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

United States, Canada
Hoffmann-La Roche

Recruiting

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Urothelial Cancer

Korea, Republic of, United States, Brazil, China, France, Germany, Mexico, Poland, Denmark, Turkey, Australia, Greece, Spain, United Kingdom, Italy
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

Urothelial Cancer

Korea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
Janssen Research & Development, LLC

Active, not recruiting

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Urothelial Cancer

United States, France, Germany, United Kingdom, Belgium, Taiwan, Spain, Israel, India, Romania, Korea, Republic of, Russian Federation, Turkey, Austria, Moldova, Republic of
Monika Joshi, MD
AstraZeneca

Active, not recruiting

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder (DUART)

Urothelial Cancer

United States
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Urothelial Cancer

United States
ALX Oncology Inc.

Recruiting

A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)

Bladder Cancer | Urothelial Carcinoma

United States
Lawrence Fong
CellSight Technologies, Inc.

Terminated

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Bladder Cancer

United States

Clinical Trials on Bladder Urothelial Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations